Signs and Symptoms

6

Review clinical trials related to Signs and Symptoms. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions

The objective of this study is to assess the safety and efficacy of the Freesolve resorbable magnesium scaffold (RMS) in the treatment of subjects with up to two de novo lesions in native coronary arteries compared to the Xience coronary drug-eluting stent (DES) system

Participants needed: 1,859
Trial details
Age: 18-80Biological sex: AllType: InterventionalSponsor: TeleflexUpdated: Jun 17, 2026Locations: 1
Eligibility criteria

Subject is ≥ 18 years and ≤ 80 years of age [+5]

Subject is hemodynamically stable with documented declining cardiac biomarkers; [+35]

Status: Recruiting

Biomedical Signal Extraction From Symptom Descriptions: An Observational Registry Using the OpenGenome Platform

This registry prospectively collects anonymized free-text symptom descriptions submitted voluntarily by adults through the OpenGenome platform at opengenome.bio. For each submission, the system retrieves real biomedical literature from PubMed and ClinicalTrials.gov in parallel, applies a constrained reasoning model operating under a strict output schema, and returns a structured biological signal report. The study evaluates the internal consistency of extracted signals, the calibration of confidence scores relative to dataset size and symptom specificity, and the distribution of biological signal categories across a large anonymous population. No intervention is assigned. No participant contact occurs. All data is anonymized at the point of collection.

Participants needed: 1,000
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: OpenGenomeUpdated: May 19, 2026Locations: 1
Eligibility criteria

Automated or programmatically generated submissions detected by rate limiting [+1]

Status: Not yet recruiting

Selective Activation of the Adrenomedullin Receptors in Migraine

Adrenomedullin is a neuropeptide implicated in the pathogenesis of migraine. This study investigates whether its administration, after pre-treatment with erenumab (a CGRP-receptor blocking monoclonal antibody), can trigger migraine attacks in individuals with migraine without aura.

Participants needed: 26
Trial details
Age: 18-65Biological sex: AllType: InterventionalSponsor: Danish Headache CenterUpdated: Mar 9, 2026Locations: 1
Eligibility criteria

Written informed consent has been obtained prior to the initiation of any study-... [+2]

History of any other primary headache disorder, except for tension-type headache... [+9]

Status: Not yet recruiting

Hypersensitivity to Amylin in Post-Traumatic Headache

Pramlintide is a peptide analogue of human amylin which is a vasoactive substance involved in the pathogenesis of headache. This study investigates whether pramlintide induces migraine-like headache in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).

Participants needed: 21
Trial details
Age: 18-65Biological sex: AllType: InterventionalSponsor: Danish Headache CenterUpdated: Jan 14, 2026Locations: 1
Eligibility criteria

Age 18 to 65 years of age upon entry into screening [+3]

> 1 mild traumatic injury to the head [+14]

Status: Not yet recruiting

Amylin-Induced Migraine Attacks Without Aura

Pramlintide is a peptide analogue of human amylin which is a vasoactive signaling molecule involved in the pathogenesis of migraine. This study investigates whether pramlintide induces migraine attacks without aura in people with migraine without aura.

Participants needed: 21
Trial details
Age: 18-65Biological sex: AllType: InterventionalSponsor: Danish Headache CenterUpdated: Jan 14, 2026Locations: 1
Eligibility criteria

Age 18 to 65 years of age upon entry into screening [+4]

Any history of a primary or secondary headache disorder other than migraine with... [+16]

Status: Recruiting

Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients

Anesthesia is a drug induced, reversible, comatose state that facilitates surgery and it is widely assumed that cognition returns to baseline after anesthetics have been eliminated. However, many patients have persistent memory impairment for weeks to months after surgery. Cardiac surgery appears to carry the highest risk of postoperative cognitive dysfunction (POCD). These cognitive deficits are associated with increased mortality, prolonged hospital stay and loss of independence. The investigators propose to investigate the role of Dexmedetomidine (DEX) in preventing long-term POCD after cardiac surgery and enhancing early postoperative recovery. It is anticipated that DEX will be the first effective preventative therapy for POCD, improve patient outcomes, and reduce length of stay and healthcare costs.

Participants needed: 2,400
Trial details
Phase: Phase 4Age: 60+Biological sex: AllType: InterventionalSponsor: Sunnybrook Health Sciences CentreUpdated: Dec 1, 2025Locations: 8
Eligibility criteria

Planned CABG (+/- valve, including off-pump) or valve replacement via sternotomy... [+1]

Lack of patient consent [+4]